NEW YORK (GenomeWeb News) – Pharmacogenomics test developer and specialty lab company Delphic has acquired the diagnostics business of iQur.
London-based iQur specializes in liver diagnostics and therapies. Delphic, which also is based in London, said in a statement that the acquisition would enable it to "leverage its capabilities and infrastructure to offer improved services in infectious diseases to the clinical and clinical trials markets, and to access the growing market for blood-borne virus screening."
iQur will continue to supply its ELF liver fibrosis test, which measures three serum markers that have been shown to correlate with the level of liver fibrosis, in partnership with Siemens.
iQur said that it would now focus on its vaccines program targeted as hepatitis, other infections, and cancer.
Financial terms of the acquisition were not disclosed.